Printed 31 October 2017
Royal Philips stated that it’ll showcase its lately expanded image-led therapy portfolio in the Transcatheter Cardiovascular Therapeutics (TCT) annual event in Denver, Colorado, that is being held between 29 October 29 and a pair of November.
Having a concentrate on cardiac and endovascular care, at TCT Philips will reveal its advanced interventional imaging systems, diagnostic and therapeutic devices, planning and navigation software, and services.
Philips is going to be showcasing its latest cardiac care solutions in ultrasound and image led therapy to supply enhanced patient care over the health continuum. Philips may also display its Dynamic Coronary Roadmap 2. with FFR/iFR Roadmap feature, so it lately received 510(k) clearance in the U.S. Fda (Food and drug administration) to promote. Philips’ unique portfolio enables clinicians to determine, guide, treat and ensure the right procedure, for the exact purpose to boost patient care at lower costs.
Next-generation image-led therapy platform
Every single day, a couple of,200 Americans die of coronary disease, averaging one dying every 40 seconds . Within the U . s . States alone, 92 million adults live with coronary disease. Now more than ever before, the requirement for integrated image-led therapy solutions that connect interventional staff people, technology and knowledge is crucial.
Harnessing vital procedural information from various sources, for example imaging systems, interventional devices, navigation tools and patient health records, Philips’ Azurion next-gen image-led therapy platform offers a strategy to provide interventional staff people using the control and knowledge they have to perform procedures efficiently. Complementing Philips’ interventional X-ray systems, Philips also provides next-gen 3D TEE technology, which supplies for brand new amounts of live 3D imaging.
Onpar gps incorporate a new acoustic design with greater frequencies and bandwidth to supply elevated resolution and tissue filling. Furthermore, fast, simple and easy , confident transthoracic and transesophageal echo enables clinicians to identify surgical pathology instantly.
Philips may also debut its Refinity ST, the following-generation rotational intravascular ultrasound (IVUS) catheter. With exceptional deliverability, 5F guide compatibility, and 45 MHz high-resolution image, Refinity ST is made to help clinicians meet the requirements of the most complex percutaneous coronary interventional cases.
The lately Food and drug administration-removed iFR Roadmap technology, only at Philips’ interventional labs, enables physicians to navigate vessels and coronary arterial blood vessels instantly, guiding decision-making in treating coronary heart.
Philips’ CoreVision iFR co-registration solution along with the main IVUS and physiology technology, may be used within the stenting process when lesions tend to be more complex. CoreVision may be used in almost any interventional lab to map pressure gradients to the angiogram for precise lesion location, severity and length measurements.
Therapeutic devices ]
The current purchase of Spectranetics expands Philips’ selection of therapy devices for coronary and peripheral artery disease. Only at that year’s congress, Philips will feature the Stellarex drug-coated balloon. Stellarex delivers top-tier clinical recent results for present with complex patients, targeting an underserved need within the fast growing peripheral vascular market.
Because the only commercially accessible drug-coated balloon with two reported randomized controlled trials, Stellarex has shown durability with consistently high patency rates in an array of patients.
“TCT offers the chance for all of us to talk about our expanded portfolio that aims to assist individuals impacted by coronary disease to return to living their lives,” stated Bert van Meurs, Business Leader Image Led Therapy for Philips. “In the congress this season, we’ll demonstrate how we are furthering our goal to assist clinicians decide, guide, treat and ensure the best therapies for his or her patients and supply safe and personalized treatments to allow faster recoveries while reducing costs.”
In the TCT booth this season, Philips may also host a number of short, daily presentations and live situation demonstrations on optimizing patient take care of coronary disease. Furthermore, Philips and Spectranetics holds a lunch symposium every day of TCT on various topics including, “Condition-of-the-art” PCI approach (learnings from SYNTAX II), imaging technologies for brand new valve therapies, and optimizing outcomes in coronary heart.
Source: Company Pr Release